Last edition
News about "Multiple Myeloma "
GSK to Acquire Chimagen's Trispecific T-Cell Engager for Multiple Myeloma
GSK agrees to acquire global rights to Chimagen Biosciences’ investigational trispecific T-cell engager for multiple myeloma in a deal valued at up to USD 750 million.
Multiple Myeloma | 16/09/2026 | By News Bureau
Bristol Myers Squibb’s arlo-cel demonstrated statistically significant and clinically meaningful responses in patients with quadruple-class exposed relapsed and refractory multiple myeloma.
Multiple Myeloma | 09/09/2026 | By News Bureau | 109
US FDA Grants Accelerated Approval to BMS' ZENBEXUS for Multiple Myeloma
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) ZENBEXUS, a first-in-class CELMoD therapy combined with daratumumab and dexamethasone for multiple myeloma.
Multiple Myeloma | 14/08/2026 | By News Bureau | 121
US FDA Grants Accelerated Approval to BMS' ZENBEXUS for Multiple Myeloma
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) ZENBEXUS, a first-in-class CELMoD therapy combined with daratumumab and dexamethasone for multiple myeloma.
Multiple Myeloma. | 14/08/2026 | By News Bureau | 121
US FDA Approves Subcutaneous Sarclisa for Multiple Myeloma Across All Existing Indications
Sanofi’s SC formulation becomes the first oncology therapy approved for administration via both an on-body injector and manual subcutaneous injection, offering shorter treatment times for patients.
Multiple Myeloma | 13/07/2026 | By News Bureau
GSK plc Secures China Approval for Blenrep Combination Therapy in Multiple Myelom
National Medical Products Administration approves Blenrep with bortezomib and dexamethasone for relapsed or refractory patients, backed by strong phase III trial outcomes.
Multiple Myeloma | 21/04/2026 | By News Bureau | 157
Biocon Biologics Secures US FDA Approval for Denosumab Biosimilars Bosaya and Aukelso
The US Food and Drug Administration (FDA) has approved Biocon Biologics' denosumab biosimilars, Bosaya (denosumab-kyqq) 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection in a single-dose vial, biosimilars of Prolia and Xgeva, respectively.
Multiple Myeloma | 17/09/2025 | By Dineshwori | 548
Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma
BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.
Multiple Myeloma | 07/04/2025 | By Aishwarya | 390
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy